USA As Represented by Secretary of the Navy

The University of Texas System

Tadeusz Kochel

Kevin R Porter

Stephen L Hoffman

Allan R Brasier

Hyunsu Ju

Adrian Recinos

Heidi Spratt

Curtis G Hayes

Josefina Nores Garcia

Ryan C Maves

Kanakatte Raviprakash

The present invention provides methods for detecting, analyzing, and identifying biomolecules used to identifying patient with dengue-like symptom who are at risk of DHF. The inventive method comprises detecting in a sample from a subject dengue infected patient one or more biomarkers selected from the group consisting of IL-10, fibrinogen, C4A, immunoglobulin, tropomyosin, and three isoforms of albumin, and which are used in a predictive MARS model to detect patients with risk of developing DHF.

Methods and biomarkers for the detection of dengue hemorrhagic fever

A method to prepare inactivate viral vaccine by exposing the virus to a predetermined concentration of an inactivating psoralen, and a preselected intensity of ultraviolet radiation for a time period sufficiently long to render the virus non-infectious but less than that which would result in degradation of its antigenic characteristics.

Psoralen-inactivated viral vaccine and method of preparation

A vaccine for promoting an immune response in a mammalian subject includes a eucaryotic plasmid expression vector which include at least part of the envelope gene and optionally, the PreM gene of dengue virus. In order to minimize immune enhancement, vaccines of up to the four serotypes of dengue are combined in a single vaccine. The vaccine in a suitable pharmaceutical carrier constitutes a pharmaceutical composition which is injected into the subject.

Dengue nucleic acid vaccines that induce neutralizing antibodies

Growing community of inventors

Frederick, MD, United States of America

Tadeusz Kochel